[144] DexCom, Inc. SEC Filing

Rhea-AI Filing Summary

DexCom (DXCM) Form 144 notice reports a proposed sale of 2,750 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $220,797.50 and approximately 392,155,265 shares outstanding. The shares were acquired as vested RSUs on 05/19/2022 and payment was recorded the same day. The filer notes an approximate sale date of 08/15/2025. The filing also discloses two prior sales by the same account: 2,750 shares on 06/16/2025 for $228,604.75 and 2,750 shares on 07/15/2025 for $234,216.67. The notice includes standard Rule 144 representations but contains no entered dates or signature data in the remarks section.

Insights

Securities Analyst

TL;DR: Insider plans to sell 2,750 vested RSU shares via UBS; prior recent sales of identical amounts were disclosed.

The filing documents a routine Rule 144 sale of 2,750 common shares through UBS Financial Services with an indicated sale date of 08/15/2025. Acquisition details show these shares were vested RSUs acquired and paid for on 05/19/2022. The filer also reported two recent sales in June and July 2025, each of 2,750 shares, with gross proceeds disclosed. From a market-impact perspective, the absolute size is small relative to the reported outstanding shares, and the disclosure follows required Rule 144 reporting conventions. The absence of completed entries in the remarks/signature area should be confirmed as an administrative omission.

Corporate Compliance Officer

TL;DR: Filing appears procedurally standard but includes missing entries in the remarks/signature fields that warrant attention.

The Form 144 provides the necessary transaction tables: issuer, broker, class, amount, market value, acquisition source (vested RSUs), and prior sales in the past three months. These elements satisfy core Rule 144 disclosure requirements. However, the remarks and signature block lacks populated date and signature information in the provided content, which could be an administrative deficiency if absent from the original submission. Ensuring the form is fully completed and signed is important for regulatory completeness.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	2750	220797.50	392155265	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/19/2022	Vested RSUs	Issuer			2750	05/19/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Foletta Family Trust c/o 6340 SEQUENCE DRIVE San Diego CA 92121	Common	06/16/2025	2750	228604.75
The Foletta Family Trust c/o 6340 SEQUENCE DRIVE San Diego CA 92121	Common	07/15/2025	2750	234216.67

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)